Tag - ATHA

Developments

Athira presents biomarker data in Alzheimer’s

Athira Pharma (NASDAQ:ATHA) is presenting new data supporting its pipeline of small molecule therapeutic candidates designed to enhance the HGF/MET neurotrophic system at the Alzheimer’s Association International...

July 17, 2023

Markets

BTIG starts Athira Pharma at buy; PT $33

BTIG launched coverage of Athira Pharma (NASDAQ:ATHA) with a “buy” rating and $33 price target. The stock closed at $8.84 on May 9. Athira is developing fosgonimeton for the treatment of Alzheimer’s disease, pervasive...

May 10, 2022

Developments

Athira Pharma extends open label extension AD studies with fosgonimeton

Athira Pharma (NASDAQ:ATHA) is extending the length of the current open label extension study for its Phase 3 LIFT-AD and Phase 2 ACT-AD studies of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s...

May 9, 2022

Feature

Athira Pharma advancing new therapies for neurodegeneration, neuronal health

Athira Pharma (NASDAQ:ATHA) is in late- and mid-stage clinical development of small molecules to restore neuronal health and slow neurodegeneration of diseases, such as Alzheimer’s, Parkinson’s and dementia.

February 8, 2022

Developments

Athira initiates dosing in Phase 2 Alzheimer’s disease study

Athira Pharma (NASDAQ:ATHA) initiated patient dosing in its ACT-AD Phase 2 trial evaluating ATH-1017 in patients with mild-to-moderate Alzheimer’s disease (AD). ATH-1017 is a small molecule designed to regenerate...

December 1, 2020

Developments

Athira initiates dosing in Phase 2/3 Alzheimer’s disease study

Athira Pharma (NASDAQ:ATHA) initiated patient dosing in its Phase 2/3 trial evaluating ATH-1017 for the treatment of mild-to-moderate Alzheimer’s disease. ATH-1017 is a small molecule designed to regenerate brain...

October 1, 2020

Tag - ATHA

Athira presents biomarker data in Alzheimer’s

BTIG starts Athira Pharma at buy; PT $33

Athira Pharma extends open label extension AD studies with fosgonimeton

Athira Pharma advancing new therapies for neurodegeneration, neuronal health

Athira initiates dosing in Phase 2 Alzheimer’s disease study

Athira initiates dosing in Phase 2/3 Alzheimer’s disease study

General

More